On August 2, 2026, Integer Holdings Corporation entered into a definitive Agreement and Plan of Merger with Armstrong Parent, Inc., an affiliate of Kohlberg Kravis Roberts & Co. L.P. (KKR). Under the terms of the transaction, KKR will acquire Integer Holdings in an all-cash deal valued at $127 per share for outstanding common stock. The merger is subject to customary closing conditions, including stockholder approval and antitrust clearances under the Hart-Scott-Rodino Act, with an outside date of May 2, 2027. Financing commitments have been secured from KKR funds and third-party lenders. Termination fees are set at $154 million payable by Integer Holdings for certain terminations and $307 million payable by Parent for breach or failure to close. The company operates in the medical device industry, manufacturing surgical instruments and implants.

On August 3, 2026, Integer Holdings Corporation announced it has entered into a definitive agreement to be acquired by affiliates of Kohlberg Kravis Roberts & Co. L.P. (KKR) in an all-cash transaction valued at approximately $5.7 billion enterprise value. Under the terms, stockholders will receive $127 per share, representing premiums of 51.8% and 28.8% over specific prior reference prices. The Integer Board unanimously approved the deal and recommends shareholder approval. The transaction is expected to close by year-end, subject to customary conditions including regulatory approvals and stockholder consent. Upon completion, Integer will become a privately held company and its common stock will be delisted from the New York Stock Exchange. Integer Holdings Corporation operates as a leading global medical device contract development and manufacturing organization (CDMO).

Integer Holdings Corporation announced its second quarter 2026 financial results and entered into a definitive agreement for KKR to acquire the company in an all-cash transaction valued at an enterprise value of $5.7 billion. Under the terms, stockholders will receive $127 per share in cash. For the quarter ended July 3, 2026, sales decreased 2.6% to $464 million, while non-GAAP adjusted EPS totaled $1.60. The company is withdrawing its financial outlook and canceling its scheduled earnings conference call due to the pending transaction. Integer Holdings Corporation operates in the medical device contract development and manufacturing industry.

Integer Holdings Corporation announced that Jim Stephens, currently President of Cardiac Rhythm Management & Neuromodulation, will transition to Executive Vice President, Special Projects effective June 29, 2026. This role is scheduled to conclude on March 31, 2027. Under a letter agreement dated June 26, 2026, if a Change of Control occurs before the termination date and Mr. Stephens remains employed through that date, his departure will be treated as a termination without Cause per his existing agreement. Mr. Stephens will be ineligible for short-term or long-term incentive awards in 2027. Integer Holdings Corporation is a medical device contract manufacturer.